Inventiva (IVA) Liabilities and Shareholders Equity (2018 - 2025)
Inventiva (IVA) recorded quarterly Liabilities and Shareholders Equity of $290.4 million in Q4 2025, down 99.86% quarter-over-quarter from $202.6 billion in Q2 2025, and up 128.46% on a YoY basis from $127.1 million in Q4 2024.
Inventiva (IVA) Liabilities and Shareholders Equity (2018 - 2025) Analysis & Trends
Inventiva's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $290.4 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 128.46% year-over-year to $290.4 million; the TTM figure through Dec 2025 stood at $203.0 billion (up 78694.75% YoY), while the FY2025 annual figure was $290.4 million, up 128.46% from the prior year.
- Liabilities and Shareholders Equity was $290.4 million for Q4 2025 at Inventiva, down from $202.6 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $202.6 billion in Q2 2025 to a low of $115662.5 in Q2 2022.
- Historically, Liabilities and Shareholders Equity has averaged $18.5 billion across 5 years, with a median of $127.1 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity plunged 99.92% in 2022, then surged 977941.76% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $139.5 million in 2021, then slipped by 15.19% to $118.4 million in 2022, then plunged by 36.76% to $74.8 million in 2023, then soared by 69.86% to $127.1 million in 2024, then jumped by 128.46% to $290.4 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $290.4 million (Q4 2025), $202.6 billion (Q2 2025), and $127.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 640.56 Mn |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | 290.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 290.44 Mn |
| Jun 30, 2025 | 202.57 Bn |
| Dec 31, 2024 | 127.13 Mn |
| Jun 30, 2024 | 20.71 Mn |
| Dec 31, 2023 | 74.84 Mn |
| Oct 11, 2023 | 34.96 Mn |
| Dec 31, 2022 | 118.35 Mn |
| Jun 30, 2022 | 115,662.54 |
| Dec 31, 2021 | 139.55 Mn |
| Jun 30, 2021 | 141.16 Mn |
| Mar 31, 2021 | 159.49 Mn |
| Dec 31, 2020 | 165.63 Mn |
| Jun 30, 2020 | 75.70 Mn |
| Dec 31, 2019 | 63.05 Mn |
| Dec 31, 2018 | 91.10 Mn |